Press Releases and Recent Developments
Emmie Fan, CEO of ImmunoKite Therapeutics, presented during the Innovation Pitch Challenge (IPC) at the conference of Redefining Early-Stage Investment (RESI) JPM 2024.
Jan 9, 2024
ImmunoKite Therapeutics was accepted in the final round of Innovation Pitch Challenge (IPC) at the conference of Redefining Early-Stage Investment (RESI) JPM 2024
Dec 4, 2023
Akeso Therapeutics was officially changed to ImmunoKite Therapeutics
Nov 15, 2023
Ms. Emmie Fan was appointed as the Chief Executive Officer (CEO) for ImmunoKite Therapeutics
Nov 15, 2023
Received the NIH (NCI) Small Business Innovation Research (SBIR) Phase I Award
June 13, 2023
Presented the preclinical study results of our lead asset, IMK-101 during its poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (December 10-13, 2022) in New Orleans, LA.
Dec 10, 2022
